Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bellicum Pharmaceuticals Inc (BLCM)

Bellicum Pharmaceuticals Inc (BLCM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Bellicum Pharmaceuticals Inc 3730 Kirby Drive Suite 1200 Houston TX 77098 USA

www.bellicum.com P: 281-454-3424

Sector:

Medical

INDUSTRY GROUPING:

Medical - Drugs

Description:

Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on discovering and developing cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. The Company's lead clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials. It is also developing BPX-201, a dendritic cell cancer vaccine, which is in a Phase I clinical trial for the treatment of metastatic castrate-resistant prostate cancer. Bellicum Pharmaceuticals, Inc. is based in Houston, Texas.

Key Statistics

Overview:

Market Capitalization, $K 727
Enterprise Value, $K -3,073
Shares Outstanding, K 9,717
Float, K 8,716
% Float 89.70%
Short Volume Ratio 0.15
% of Insider Shareholders 10.30%
% of Institutional Shareholders 4.93%

Financials:

Annual Sales, $ 1,500 K
Annual Net Income, $ -24,970 K
Last Quarter Sales, $ 1,000 K
Last Quarter Net Income, $ -760 K
EBIT, $ -23,840 K
EBITDA, $ -23,830 K

Growth:

1-Year Return -91.18%
3-Year Return -98.32%
5-Year Return -99.77%
5-Year Revenue Growth 689.47%
5-Year Earnings Growth 100.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.02 on 11/14/23
Next Earnings Date 03/05/24
Earnings Per Share ttm -0.52
EPS Growth vs. Prev Qtr 91.67%
EPS Growth vs. Prev Year 91.30%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-10 on 02/06/20

BLCM Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -157.93%
Profit Margin % -1,664.67%
Debt/Equity 0.00
Price/Sales 12.72
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share 0.48
Interest Coverage -3.37
60-Month Beta 1.39
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar